X4 Pharmaceuticals, Inc.
General ticker "XFOR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $52.2M (TTM average)
X4 Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -10.9%.
Estimated limits based on current volatility of 6.2%: low 3.13$, high 3.55$
Factors to consider:
- Total employees count: 93 (+32.9%) as of 2023
- Top business risk factors: Liquidity and credit risks, Operational and conduct risks, Labor/talent shortage/retention, Intellectual property risks, Geopolitical risks
- Current price 48.7% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.40$, 23.76$]
- 2025-12-31 to 2026-12-31 estimated range: [4.71$, 15.51$]
Financial Metrics affecting the XFOR estimates:
- Negative: with PPE of -3.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -95.00 <= 0.33
- Positive: Investing cash flow per share per price, % of 48.62 > -0.66
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 15.12 <= 18.93
Short-term XFOR quotes
Long-term XFOR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $2.56MM |
| Operating Expenses | $87.57MM | $107.52MM | $38.96MM |
| Operating Income | $-87.57MM | $-107.52MM | $-36.40MM |
| Non-Operating Income | $-6.27MM | $6.43MM | $-0.74MM |
| Interest Expense | $3.99MM | $5.78MM | $8.77MM |
| R&D Expense | $61.06MM | $72.02MM | $81.64MM |
| Income(Loss) | $-93.84MM | $-101.09MM | $-37.14MM |
| Taxes | $0.03MM | $0.08MM | $0.31MM |
| Profit(Loss)* | $-93.87MM | $-101.17MM | $-37.45MM |
| Stockholders Equity | $74.05MM | $51.10MM | $22.15MM |
| Inventory | $0.00MM | $0.00MM | $2.82MM |
| Assets | $155.59MM | $147.26MM | $146.45MM |
| Operating Cash Flow | $-77.10MM | $-96.51MM | $-130.90MM |
| Capital expenditure | $0.10MM | $0.06MM | $0.33MM |
| Investing Cash Flow | $-0.10MM | $-14.88MM | $66.99MM |
| Financing Cash Flow | $117.23MM | $88.52MM | $20.29MM |
| Earnings Per Share** | $-45.53 | $-17.07 | $-5.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.